Skip to main content

Vecuronium Disease Interactions

There are 3 disease interactions with vecuronium:

Major

Neuromuscular blocking agents (applies to vecuronium) liver disease

Major Potential Hazard, High plausibility.

Neuromuscular blocking agents undergo metabolism by the liver. Elimination and effects may be prolonged in patients with liver disease. Therapy with neuromuscular blocking agents should be administered cautiously in patients with liver disease.

References

  1. "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.
  2. "Product Information. Nuromax (doxacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  3. "Product Information. Zemuron (rocuronium)." Organon, West Orange, NJ.
  4. "Product Information. Metubine Iodide (metocurine)." Dista Products Company, Indianapolis, IN.
  5. "Product Information. Mivacron (mivacurium)." Glaxo Wellcome, Research Triangle Park, NC.
View all 5 references
Major

Neuromuscular blocking agents (applies to vecuronium) paresis

Major Potential Hazard, High plausibility. Applicable conditions: Paralytic Disorder

Patients with hemiparesis or paraparesis may require higher dosages of non-depolarizing neuromuscular blocking agents in the affected limbs. Neuromuscular monitoring should be performed on a non-paretic limb to avoid inaccurate dosing.

References

  1. "Product Information. Tracrium (atracurium)." Glaxo Wellcome, Research Triangle Park, NC.
  2. "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.
  3. "Product Information. Metubine Iodide (metocurine)." Dista Products Company, Indianapolis, IN.
  4. "Product Information. Mivacron (mivacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  5. "Product Information. Zemuron (rocuronium)." Organon, West Orange, NJ.
  6. "Product Information. Nuromax (doxacurium)." Glaxo Wellcome, Research Triangle Park, NC.
View all 6 references
Major

Neuromuscular blocking agents (applies to vecuronium) pulmonary impair

Major Potential Hazard, High plausibility. Applicable conditions: Pulmonary Impairment

Neuromuscular blocking agents can cause respiratory depression and paralysis. Therapy with neuromuscular blocking agents should be administered cautiously in patients with pulmonary impairment. Treatment of respiratory paralysis consists of positive-pressure artificial respiration with oxygen and maintenance of a patent airway until the recovery of normal respiration is assured.

References

  1. "Product Information. Tracrium (atracurium)." Glaxo Wellcome, Research Triangle Park, NC.
  2. "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.
  3. "Product Information. Metubine Iodide (metocurine)." Dista Products Company, Indianapolis, IN.
  4. "Product Information. Mivacron (mivacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  5. "Product Information. Nuromax (doxacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  6. "Product Information. Anectine (succinylcholine)." Glaxo Wellcome, Research Triangle Park, NC.
  7. "Product Information. Zemuron (rocuronium)." Organon, West Orange, NJ.
View all 7 references

Vecuronium drug interactions

There are 170 drug interactions with vecuronium

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.